Notably, in ultraselect patients with right-sided tumors characterized by specific gene alterations (RAS/BRAF/EGFR ectodomain wild type), early tumor shrinkage and depth of response may serve as prognostic markers for chemotherapy plus anti-EGFR antibody treatment. Here, BRAF is linked to neoplasm.